E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 4/30/2020 in the Prospect News Distressed Debt Daily.

Purdue Pharma marks $25 million March operating profit; sales rise

By Caroline Salls

Pittsburgh, April 30 – Purdue Pharma LP posted a $25 million operating profit for March on $78 million in net sales, according to its monthly operating report filed Thursday with the U.S. Bankruptcy Court for the Southern District of New York.

In comparison, the company reported a $29 million operating profit for February on $67 million in net sales.

In addition, Purdue Pharma listed $1,063,000,000 in cash and cash equivalents as of March 31, down from $1,152,000,000 at the end of February.

Purdue Pharma is a Stamford, Conn.-based drug manufacturer. It filed for Chapter 11 bankruptcy on Sept. 15, 2019 under case number 19-23649.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.